A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Eribulin (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Inc
- 30 Jan 2017 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
- 30 Jan 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Jun 2018.
- 31 May 2014 New source identified and integrated (Mayo Clinic, 13-002454 )